stockrowVanda Pharmaceuticals Inc.
VNDAVanda Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $216.1 million, up 8.72% from fiscal 2024.
- Revenue
- +24.1%
- EPS
- +1.82%
- Free cash flow
- +9.57%
- Total debt
- −16.5%
Quarter to September 2026, against a year earlier
Follow VNDA
Alert me
Vanda Pharmaceuticals Inc. (VNDA) Return on invested capital
Vanda Pharmaceuticals Inc.'s return on invested capital over the twelve months to 30 September 2026 was −180.2%, down 40.0 percentage points from fiscal 2025 (−140.2%). Over the past ten years it has ranged from −140.2% (fiscal 2025) to 75.2% (fiscal 2018) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −140.2% | (124.94) |
| FY2024 | −15.2% | (9.64) |
| FY2023 | −5.57% | (11.29) |
| FY2022 | 5.72% | (26.35) |
| FY2021 | 32.1% | 14.52 |
| FY2020 | 17.6% | 4.74 |
| FY2019 | 12.8% | (62.41) |
| FY2018 | 75.2% | 75.22 |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | 0.00 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| KRRO Korro Bio, Inc. compare | 0.00% |
| ABEO Abeona Therapeutics Inc. compare | 0.00% |
| CABA Cabaletta Bio, Inc. compare | 0.00% |
| FATE Fate Therapeutics, Inc. compare | 0.00% |
| GLSI Greenwich LifeSciences, Inc. compare | 0.00% |
| ACIU AC Immune compare | 0.00% |
| VNDA Vanda Pharmaceuticals Inc. | −180.2% |
| IMRX Immuneering Corporation compare | −198.4% |
| SLGL Sol-Gel Technologies Ltd. compare | −6,630.2% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)